SYRE · Spyre Therapeutics, Inc.

The thesis

Spyre Therapeutics' three inflammatory bowel disease (IBD) antibodies each cleared single-agent proof of concept, and the shares have recovered above the $85.00 price of the 5 October 2026 stock sale. The Q4 2026 SPY072 arthritis readouts decide whether its TL1A antibody works as a standalone drug outside IBD.

The shares closed at $92.91 on 26 October 2026, 14.7% below the 52-week high of $108.92 and up from $80.45 on 13 October 2026. The 14-day relative strength index, a 0-to-100 gauge of recent buying pressure, reads 68.3. The shares are down 5.1% over three months.

The narrative is maturing: the single-agent data have been public since 8 September 2026, analyst coverage widened with the 1 October 2026 and 12 October 2026 initiations, and the combination data the platform rests on is not due until 2027. Company news since the 14 October 2026 note is presentations, not new trial results. Spyre showed clinical data for all three antibodies at United European Gastroenterology Week on 18 October 2026 and humanized-mouse colitis data on 19 October 2026, in which combinations improved on single agents. Mouse results are not human efficacy data, and the human combination readout from the SKYLINE trial is guided for 2027.

Bullish and bearish views on Spyre Therapeutics, Inc.

The bull case on Spyre Therapeutics, Inc. (SYRE), in brief: Each IBD component cleared proof of concept. The bear case: The company sold stock at $85.00.

Bull case

• Each IBD component cleared proof of concept. On 8 September 2026, SPY003 (anti-IL-23) met its primary endpoint in Part A of the Phase 2 SKYLINE trial in ulcerative colitis, with 20% clinical remission and 30% endoscopic improvement at week 12. SPY001 and SPY002 had earlier reported positive induction data, according to the company.
• Cash funds the pipeline into 2029. Spyre held $1,145.3 million in cash and marketable securities at 30 June 2026, and management projected funding into the second half of 2029 (Q2 2026 Form 10-Q, 4 August 2026). The 5 October 2026 offering added $350.0 million gross.
• Analysts remain positive. UBS initiated with a Buy rating and a $120 target on 12 October 2026. JPMorgan initiated with an Overweight rating and a $110 target on 1 October 2026. BTIG reiterated Buy with a $121 target on 19 October 2026, and Benzinga reported another analyst maintaining a bullish rating on 21 October 2026.
• The TL1A class has a Phase 3 success. Merck said on 22 June 2026 that tulisokibart met its week-12 clinical remission endpoint in the Phase 3 ATLAS-UC induction study, with no safety concerns identified. That supports the mechanism behind SPY002 and SPY072.

Bear case

• The company sold stock at $85.00. The 4,117,648-share offering raised $350.0 million gross, and TIKR reported the shares fell 14% on 6 October 2026 after the deal was upsized from an initial $250 million. A second offering in April 2026 sold 6.5 million shares at $62.00.
• The rheumatoid arthritis (RA) study missed the company's bar. On 25 August 2026, the SPY072 low dose met the DAS28-CRP primary endpoint, but the company said the effect was too small to prioritise RA monotherapy. Deutsche Bank cut its target from $135 to $127 the next day.
• More equity supply remains possible. A 26 June 2026 at-the-market agreement allows up to $500.0 million of stock sales. The underwriters' 30-day option on about $52.5 million of shares runs to about the first week of November.
• Insiders sold near $89. The chief financial officer sold 18,232 shares on 2 September 2026 at an average of $89.35, and insiders sold 114,631 shares (about $10.6 million) over 90 days, per a MarketBeat summary of Form 4 filings dated 30 September 2026.

Price setup

The close of $92.91 on 26 October 2026 sits 9.3% above the $85.00 offering price and 14.7% below the 52-week high of $108.92 (adjusted daily closes). The shares have regained the ground lost after the 6 October 2026 drop. The prior note's invalidation level of a daily close below $72 remains 22.5% under the latest close.

Crowding evidence is visible in four places: a relative strength index of 68.3, a quarterly report expected within about nine days, equity sold at $85.00 three weeks ago, and insider sales in September near $89. Wall Street coverage is broad, with at least four firms at Buy-equivalent ratings and targets of $110 to $127. The next trial data are binary, so the shares can move sharply in either direction on the SPY072 readouts.

Catalysts, next 30 days

• Q4 2026 (guided): SPY072 topline data in psoriatic arthritis and axial spondyloarthritis. After the RA result, these test whether the TL1A antibody works alone outside IBD. No exact date has been given.
• 2027 (guided): SKYLINE Part B combination data in ulcerative colitis. This is the first human evidence on whether combining the antibodies beats single drugs.

Elapsed catalysts

• ~4 November 2026 (est.): Q3 2026 financial results. Company-confirmed timing was not found; Spyre reported Q3 2025 on 4 November 2025, and TradingView lists 5 November 2026. The report updates cash after the $350.0 million offering and shows any use of the at-the-market program after 30 June 2026. (passed 1d ago)
• ~4 November to 5 November 2026 (est.): underwriters' option expiry. The 30-day option on about $52.5 million of shares shows whether the offering grows beyond $350.0 million gross. (passed 1d ago)

What would change the view

The case breaks if SPY072 misses the company's own bar for development in psoriatic arthritis or axial spondyloarthritis, or if SKYLINE Part B shows no gain from combinations over single agents. Full Merck or Roche TL1A data showing higher efficacy than Spyre's Phase 2 figures, or a class-wide safety finding, would also weaken it. On price, a daily close below $72 would end the view, as it would sit well under the $85.00 offering price and the range since the September data.

The rating stays where it was. The price rise since 13 October 2026 and the conference presentations add no new human efficacy data, so the standing evidence is unchanged.

What it trades with

Spyre trades with clinical-stage immunology and biotech shares, and with the Nasdaq Biotechnology index when risk appetite shifts. Merck's tulisokibart and Roche's afimkibart programs are the closest read-across for the TL1A antibody, and their data releases can move Spyre without any company news. Equity raises by peers at similar valuations also affect sentiment toward the group.